18 Jun 2020 OP0006

tensions or variations thereof. NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY (PASS) PROTOCOL (OP0006)

EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION not be used to support any marketing automation and the used to support any marketing automation and the support any ma SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE

Final Non-interventional PASS Protocol This document

18 Jun 2020

PASS INFORMATION

Protocol version identifier Date of last version of protocol EU PAS register number Active substance Medicinal product Product reference Marketing authorization holder (MAH) Joint PASS	2.0 Not applicable To be completed after protocol approval by EMA Romosozumab Romosozumab (AMG 785; CDP7851)
EU PAS register number Active substance Medicinal product Product reference Marketing authorization holder (MAH)	To be completed after protocol approval by EMA Romosozumab Romosozumab (AMG 785; CDP7851)
Active substance Medicinal product Product reference Marketing authorization holder (MAH)	Romosozumab (AMG 785; CDP7851)
Medicinal product Product reference Marketing authorization holder (MAH)	Romosozumab (AMG 785; CDP7851)
Product reference Marketing authorization holder (MAH)	
Marketing authorization holder (MAH)	110004465
	H0004465
Joint PASS	UCB Pharma S.A.
	Not applicable
Research question and objectives	The overarching objective of this study is to monitor the potential risk of serious infection associated with the use of romosozumab in comparison with other available osteoporosis medications in routine clinical practice in Europe
Countries of study	Denmark, France, Germany, Italy, Netherlands, Spain, and the UK
Authors	
Authors per	

MARKETING AUTHORIZATION HOLDER

Marketing authorization holder (MAH)	UCB Pharma S.A. Allée de la Recherche 60 B-1070 Brussels Belgium	tionsthere
MAH contact person		or variat
Marketing authorization holder (MAH) MAH contact person		and any extensions
	COPY application	
	ACTEDOTIZATIO	
Retro	Ino	
oport any		
sed to sult		
motheve		
hent coi		

1 TABLE OF CONTENTS

PASS INFORMATION	2 &.
 PASS INFORMATION MARKETING AUTHORIZATION HOLDER 1 TABLE OF CONTENTS 2 LIST OF ABBREVIATIONS 3 RESPONSIBLE PARTIES 4 ABSTRACT 5 AMENDMENTS AND UPDATES 6 MILESTONES 7 RATIONALE AND BACKGROUND 	
1 TABLE OF CONTENTS	
2 LIST OF ABBREVIATIONS	6 ;1015
3 RESPONSIBLE PARTIES	
4 ABSTRACT	
5 AMENDMENTS AND UPDATES	<u>چ</u> 11
6 MILESTONES	
 4 ABSTRACT	12
7.1 Product	12
7.2 Regulatory action	13
7.3 Previous observational studies	13
8 RESEARCH QUESTION AND OBJECTIVES	13
9 RESEARCH METHODS	14
9.1 Study design	14
9.2 Setting	14
9.2.1 Source population	15
9.2.2 Study period	15
9.2.3 Study population	15
9.2.4 Inclusion criteria	16
9.2.5 Exclusion criteria	16
9.2.6 Follow up	17
9.3 Variables	17
9.3.1 Exposure	17
9.3.1 Exposure	19
9.3.3 Covariates (confounders and interaction terms)	
9.3.3.1 Potential confounders	21
9.3.3.22 Interaction/stratification terms	24
9.4 Data sources	24
9.5 Study size	32
9.6 Data management	
9.5 Data management 9.61 Data management 9.61 Identification of UMLS concepts 9.6.2 Definition of data extraction algorithm 9.6.3 Event data extraction	
9.6.2 Definition of data extraction algorithm	
9.6.3 Event data extraction	
9.6.3.1 Benchmarking of incidence rates of events	
9.6.4 Data elaboration	

9.6.5 Missing data	.37
9.7 Data analysis	.38
9.7.1 Statistical elements	.38 th ^{ol}
 9.6.6 Data sharing 9.7 Data analysis	.38 . 15
9.8 Quality control	.41. 2110
9.9 Limitations of the research methods	.42
9.10 Other aspects	.43
 9.10 Other aspects 10 PROTECTION OF HUMAN SUBJECTS 11 MANACEMENT AND REPORTING OF A DVEDSE EVENTS (A DVEDSE DDUC) 	.43
11 MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE DRUG	
REACTIONS	
12 PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS	
13 REFERENCES (AVAILABLE UPON REQUEST)	.44
APPENDIX 1. LIST OF STAND-ALONE DOCUMENTS	.49
APPENDIX 2. ENCEPP CHECKLIST FOR STUDY PROTOCOLS	. 50
APPENDIX 3. LIST OF DIAGNOSIS CODES FOR STUDY OUTCOMES	.56
APPENDIX 4. VALIDATION PROCESS FOR STUDY OUTCOMES	. 58

LIST OF TABLES

Table 1:	Overview of outcome validation available with references	. 20
Table 2:	Overview of the considered databases	.26
Table 3:	Overview of the timing of data updates from participating data sources	.32
Table 4:	Target population for the descriptive and drug utilization sections of the proposed PASS - Numbers of new users of OP medications in 2016 in contributing databases	.33
Table 5:	Sample size needed under different scenarios of incidence and HR, with matching romo:comp is 1:3	. 34
anothe	LIST OF FIGURES	
Figure 1:	Representation of patient eligibility and follow-up into different treatment	

LIST OF FIGURES

	Figure 1:	Representation of patient eligibility and follow-up into different treatment cohorts	
\sim	Figure 2:	Construction of treatment episode/s for patient-level drug utilization, incidence rate/s, and comparative safety study	19
THIS	Figure 3:	Model for data sharing and elaboration	35
	Figure 4:	Process to be followed by local data processors	37

2

LIST OF ABBREVIATIONS

Abbreviation	Definition	
ALN	alendronate or alendronic acid	
ARCH	Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk	
ATC	Anatomical Therapeutic Chemical	
BMI	body mass index	
BNF	British National Formulary	
CI	confidence interval	
CPRD	Clinical Practice Research Datalink	
CV	cardiovascular	
DDD	defined daily dose	
EMA	European Medicines Agency	
EMR	electronic medical record	
ENCePP	European Network of Centres for Pharmacoepidemiology and Pharmacovigilance	
EU	European Union	
FRAME	Fracture Study in Postmenopausal Women with Osteoporosis	
GePaRD	German Pharmacoepidemiological Research Database	
GP	general practitionet	
HR	nazard ratio	
HSD	Health Search Database	
ICD-9-CM	International Classification of Diseases. revision 9, clinical modification	
ICD-10	International Classification of Diseases, revision 10	
ICPC	International Classification of Primary Care	
IPCI	Integrated Primary Care Information Project	
IR 500	incidence rate	
IRB C	institutional review board	
iv o	intravenous	
LTD	long-term disease	
МАН	Marketing Authorization Holder	
MI OP PASS	myocardial infarction	
OP	osteoporosis	
PASS	post-authorization safety study(ies)	
PMSI	hospital discharge summaries database	

Abbreviation	Definition]
PPV	positive predictive value	×.
PV	pharmacovigilance	insthereof.
RR	relative risk	Still
RMM	risk minimization measure	
RMP	Risk Management Plan	
RRE	Remote Research Environment	
SAE	serious adverse event	
SCCS	self-controlled case series	
SD	standard deviation	
SI	serious infection	
SIDIAP	Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària	
SmPC	Summary of Product Characteristics	
SNDS	Système National Des Données de Santé	
UMLS®	Unified Medical Language System]

3

Function	Na	me	Affiliation	Address
Study Coordina (UK)	tor		The Chancellor, Masters and Scholars of the University of Oxford	Wellington Squar Oxford, OX1
Study Manager (ES)			Synapse Research Management Partner	C. Velázquez 94, 1º Planta, 28006, Madrid
Information Tec Programming an Infrastructure		Prof. Dr.	Erasmus University Medical Centre	Dr. Molewaterple 40, 3015 GD Rotterdam
EU and Global Regulatory Lead Contact Person		BSc, LLB, LLM	UCB Biopharma SRL	Allée de la Recherche 60 B-1070 Brussels Belgium
Real World Evi Lead Scientist - Person (MAH)		Dr (MD, PhD)	UCB Biopharma SRL	Allée de la Recherche 60 B-1070 Brussels Belgium
Safety Lead Romosozumab Person (MAH)	- Contact	MSc	UCB Biopharma SRL	Allée de la Recherche 60 B-1070 Brussels Belgium

Function	Name	Title	Affiliation	Address
Participating countries		-		
Data source CPRD (UK)			The Chancellor, Masters and Scholars of the University of Oxford	Wellington Square, Oxford, OX1
Data source IPCI (NL)		Prof. Dr.	Erasmus University Medical Centre	Dr. Molewaterplein 40, 3015 GD Rotterdam
Data source HSD (IT)			SIMG, Società Italiana di Simg Service SRL	Via del Sansovino 179 50142, Florence
Data source SIDIAP (ES)		Dr. (MD, PhD)	IDIAP Jordi Gol	Gran Via de les Corts Catalanes, 587, 08007 àtic, Barcelona, Spain
Data source Nationwide linked Danish registries (DK)		Prof.	Department of Clinical Epidemiology at Aarhus University Hospital	Olof Palmes Alle 43-45 8200 Aarhus N Denmark
Data source GePaRD (DE)		Safety Unit	Deibniz-Institut für Präventionsforschung und Epidemiologie (BIPS)	Achterstraße 30 28359 Bremen Germany
Data source SNDS (FR)		in ⁹	Bordeaux PharmacoEpi Bordeaux (Université de Bordeaux-Adera)	146 rue Léo Saignat - Case 41 33076 Bordeaux cedex France

CEO=Chief Executive Officer; CPRD=Clinical Practice Research Datalink; DE=Germany; DK=Denmark; ES=Spain; EU=European Union; FR=France; GePaRD=German Pharmacoepidemiological Research Database; HSD=Health Search Database; IPCI=Integrated Primary Care Information Project; IT=Italy; MAH=Marketing Authorization Holder; NL=Netherlands; SIDIAP=Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària; SIMG=Societá Italiana di Medicina Generale; SNDS=Système National Des Données de Santé

4

hisdocu

ABSTRACT

Title

European non-interventional post-authorization safety study (PASS) related to serious infections (SIs) for romosozumab by the EU-ADR Alliance.

To evaluate the risk of SIs associated with the use of romosozumab in routine clinical practice compared with other available osteoporosis (OP) medications, a European multi-national, multi-database, comparative PASS will be conducted.

Rationale and background

An imbalance in the incidence of serious adverse events (SAEs) of infections was observed in the 12-month Placebo-Controlled Osteoporosis Safety Analysis Set. This imbalance was not

driven by a specific type of infection or causative micro-organism. No imbalance was observed in the alendronate (ALN)-controlled study 20110142 (ARCH). Given the imbalance of SAEs of iations thereof infections in the pooled placebo-controlled studies, SI events were included in the European Union (EU)-Risk Management Plan (RMP) as an important potential risk associated with romosozumab treatment.

Research question and objectives

The overarching objective of this study is to monitor the potential risk of SI associated with the use of romosozumab in comparison with other available OP medications in routine clinical practice in Europe.

Specifically, the study will provide further understanding on the following objectives:

- 1. To assess the incidence rate (IR) of SI in romosozumab users in the indicated population in Europe as per the Summary of Product Characteristics (SmPC), and in cohorts of users of other OP medications similar to the romosozumab indicated population in Europe as per SmPC (ie, who would also fulfil the indications/contraindications for romosozumab in Europe);
- 2. To assess the IR of SI in subgroups of romosozumab users in the indicated population in Europe as per the SmPC and amongst users of other OP medications similar to the indicated population for romosozumab in Europe as per the SmPC, after stratification by age, previous use of OP medications, and by prespecified key SI risk factors;
- 3. To compare the risk of SI in romosozumab users in the indicated population in Europe as per the SmPC to the risk of SI seen amongst users of ALN similar to the indicated population for romosozumab in Europe as per the SmPC and with similar baseline characteristics.

Study design

This will be a multi-national, multi-database cohort study of new users of romosozumab and new users of other OP medications. The study period is expected to last for 4 years (2020 to 2024).

Population

The study population will comprise of all women from the 7 participating data sources with severe OP who are dispensed or prescribed an OP medication of interest for the first time (new user) during the study period, have been continuously registered in the data source for at least 12 months prior to the first recorded dispensing/prescription of the OP medication of interest, and are at least 50 years of age on the date of the first dispensing/prescription of the OP medication of interest. Women with a diagnosis of cancer (any except basal cell skin cancer) or Paget disease at any time before treatment initiation will be excluded.

New users will be followed for a maximum of 24 months from index therapy initiation (index date). Two Follow-up Periods will be included for the estimation of SI IRs: an Exposure-based Follow-up Period and a Fixed (first exposure carried forward) Follow-up Period.

For the exposure-based analysis, participants will be followed until the occurrence of the SI event of interest, discontinuation of the study drug of interest, switch or addition of any other OP medication (except calcium/vitamin D supplements), lost to follow-up, death, end of the

12 months after therapy initiation (as per the romosozumab SmPC), or end of the study period/data extraction date. For the Fixed Follow-up Period, participants will be followed in their

(primary active comparator), other oral bisphosphonates (ibandronate or risedronate at doses indicated for OP treatment), intravenous (iv) bisphosphonates (zoledronate or ibandronate at doses indicated for OP treatment), denosumab (at the dose indicated for OP treatment). and teriparatide. Primary outcome is SI leading to hospitation operationalized

operationalized as either of in-hospital death with a diagnosis of infection during the same admission/episode or recorded diagnosis of any infection followed by death in the subsequent month.

Other covariates and potential confounding factors will be identified at cohort entry (index date) based on the patients' records in the previous 12 months (Baseline Period), and will include general patient characteristics, SI risk factors, markers of OP severity, and use of other medications at baseline, as described in detail in Section 9.3.3

Data sources

This study will be conducted using routinely collected data from different data sources that participate in the EU-ADR Alliance, with the addition of databases from the UK (Clinical Practice Research Datalink [CPRD] GOLD), Germany (German Pharmacoepidemiological Research Database [GePaRD]), and France (Système National Des Données de Santé [SNDS] database). Participants from 7 European countries will provide heterogeneous and representative data on the safety of romosozumab as well as ensuring sufficient statistical power for the study.

Study size

Feasibility estimates demonstrate the capability of the consortium and the data sources to capture a sufficient sample of patients in each OP medication group. The number of romosozumab users and comparator users needed to obtain an alpha risk of 0.05 with 90% power in a 1:3 (romosozumab:comparator) matched cohort analysis for different scenarios of incidence of SI events and hazard ratio (HR) were calculated. In the worst-case scenario of IRs of 2.5 per 100 person-years and a 2.2-fold relative increase in risk, 900 romosozumab users would be required (and 2,700 users of the active comparator).

Data Analysis

The IRs of SI for each OP medication will be calculated for the 2 Follow-up Periods. Incidence rates and 95% confidence intervals (CIs) of SI events of interest will be calculated for each study drug using a Poisson model. If there is overdispersion, a negative binomial model will be used instead.

For the Fixed Follow-up Period, IR of patients with SI events of interest will also be reported.

20

The SI event/s rates (as in Objectives 1 and 2) for each study drug will be provided stratified by key SI risk factors. For Objective 3 (the comparative safety analysis), the Cox regression model

score matching as well as negative control outcomes analyses to identify unobserved confounding. If required, additional analyses will be conducted to assess the effects of potential biases related to insufficient control for confounding/channeling bias: (i) empirical calibration using negative control outcomes; (ii) self-controlled case series (SCCC) variable analysis.

Milestones

Annual reports will be submitted for 4 years. Upon the minimum sample size being reached, the comparative safety analysis will be conducted and reported as part of the next interim and/or final report/s. The study will continue to completion (4 years) even if the sample size is reached before the 4 years to allow variability and better precision in the estimates of IR and HR.

AMENDMENTS AND UPDATES 5

Protocol changes may affect the legal and ethical status of the study and may also affect the statistical evaluations of sample size and the likelihood of the study fulfilling its primary objective.

Significant changes to the protocol will only be made as an amendment to the protocol and must be approved by UCB, institutional review board (IRB)/independent ethics committee, regulatory authorities and local institutions (if required), prior to being implemented.

rhis document cannot be used to support any main

6 MILESTONES

Milestone	Planned date*
Protocol submission to EMA	04 Feb 2020
Protocol approval by EMA	,S ¹
Registration of the EU PAS register	
Start of data collection (year 1)	Valle
End of data collection (year 1)	E OY
Interim report 1-explanatory features of dataset	ions
Start of data collection (year 2)	Ner"
End of data collection (year 2)	ot
Interim report 2-explanatory features of dataset	× 2(,)
Start of data collection (year 3)	all
End of data collection (year 3)	,
Interim report 3-explanatory features of dataset and comparative analysis	
Start of data collection (year 4)	
End of data collection (year 4)	
Final report	

EMA=European Medicines Agency; EU=European Union; PAS=post-authorization study

* The dates for the milestones will be included after the protocol is approved by EMA.

7 RATIONALE AND BACKGROUND

7.1 Product

Romosozumab (Anatomical Therapeutic Chemical [ATC] code: M05BX06) is a bone-forming monoclonal antibody that binds to and inhibits sclerostin, with a dual effect of increasing bone formation and decreasing bone resorption (McClung et al, 2014; Padhi et al, 2011).

In postmenopausal women with OP and previous fragility fracture/s, romosozumab followed by ALN showed superior efficacy to standard of care ALN alone in reducing fracture risk (pivotal study 20110142 [ARCH]). Romosozumab was also superior to placebo in reducing fracture risk in postmenopausal women with OP (pivotal study 20070337 [FRAME]).

Romosozumab is indicated for the treatment of severe OP in postmenopausal women at high risk of fracture with the following contraindications: history of myocardial infarction (MI) or stroke, hypersensitivity to the active substance(s) or to any of the excipients, and hypocalcaemia.

An imbalance in the incidence of SAEs of infections was observed in the pooled placebo-controlled studies. In the 12-month Placebo-Controlled Osteoporosis Safety Analysis Set, overall incidence of SAEs of infections was 1.9% in romosozumab-treated subjects and 1.3% in placebo-treated subjects, with a relative risk (RR) of 1.49 (95% CI: 1.04, 2.13). This

treatment difference was not driven by a specific type of infection or causative micro-organism. Of note, no imbalance was observed for adverse events of infections (serious and nonserious), itations thereof either in pooled placebo-controlled studies or the ALN-controlled study 20110142 (ARCH). In the latter, the incidence of SIs was 2.3% in romosozumab-treated subjects and 2.4% in ALN-treated subjects (RR=0.97; 95% CI: 0.65, 1.44) during the 12-month, Double-Blind Period.

Based on the above observation, SIs were included in the EU-RMP for romosozumab as an important potential risk.

To evaluate the risk of SIs associated with the use of romosozumab in routine clinical practice compared with other available OP medications, a European multi-national, multi-database, ettensit comparative PASS will be conducted.

7.2 **Regulatory action**

This EU SI PASS is part of a PASS program aimed at monitoring the safe use of romosozumab in European populations within the framework of a comprehensive RMP. In addition to the EU SI PASS, the PASS program encompasses a study on the use of romosozumab and adherence to indication and contraindication as per the approved SmPC (Risk Minimization Measure [RMM] PASS), and a cardiovascular (CV) comparative safety study (CV PASS).

Previous observational studies 7.3

This will be the first PASS conducted to study the risk of SI associated with the use of romosozumab under routine clinical practice in Europe. Routine postmarketing pharmacovigilance (PV) data are being collected in parallel in other regions of the world, including US and Japan.

RESEARCH QUESTION AND OBJECTIVES 8

The overarching objective of this study is to monitor the potential risk of SI associated with the use of romosozumab in comparison with other available OP medications in routine clinical practice in Europe.

Specifically, the study will provide further understanding on the following specific objectives:

- 1. To assess the IR of SI in romosozumab users in the indicated population in Europe as per the SmPC, and in cohorts of users of other OP medications similar to the romosozumab indicated
- population for romosozumab in Europe as per the SmPC, after stratification by age, previous
 - To compare the risk of SI in romosozumab users in the indicated population in Europe as per the SmPC to the risk of SI seen amongst users of ALN similar to the indicated population for romosozumab in Europe as per the SmPC and with similar baseline characteristics.

18 Jun 2020 OP0006

RESEARCH METHODS 9

9.1 Study design

conort study of new users of romosozumab and new inconcations. This is a state-of-the-art study design in pharmacoepidemiology as endorsed by the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) guidelines on methodological standards (European Medicines Agency [EMA]/95098/2010, Rev 7).
Objectives 1 and 2, as outlined in Section 8, will report IRs of SI events (here the state of the SmPC, and in patients).

- romosozumab as per the approved SmPC.
- For Objective 3, a parallel cohort design will be used, matched on propensity scores and will compare the risk of SI events in new users of romosozumab adherent to the indicated population defined in the SmPC, compared to new users of ALN with similar baseline characteristics.

9.2 Setting

Participants from 7 European countries, including North, South and Central Europe, will be included. Data from primary care, secondary care, health registers, prescription/dispensation registers and claims will be utilized.

The EU-ADR Alliance, an alliance of academic research center with expertise in pharmacoepidemiological research within the EU, will conduct this study. The EU-ADR Alliance was created to undertake PV studies and have worked on 7 drug safety projects, consolidating results from the datasets in the different countries. Data from the following 5 current EU-ADR Alliance member electronic healthcare databases will be obtained for this study: the Integrated Primary Care Information Project (IPCI) from the Netherlands, the Health Search Database (HSD) from Italy, the Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària (SIDIAP) from Spain, the data linked from the population-based administrative and health registries in Denmark, and CPRD from the UK. The latter will be obtained through an existing license by the Marketing Authorization Holder (MAH).

Furthermore, with the aim of increasing the potential number of romosozumab users under study, and to maximize the representativeness of the study findings, 2 additional databases from Germany and France have been integrated into the network and will be accessed through an existing collaboration agreement. From Germany, GePaRD will provide access in collaboration with the Leibniz Institute for Preventions Research and Epidemiology (BIPS). From France, the (French nationwide healthcare data system (SNDS) with linkage from the national outpatients claims database (Système National d'Information Inter-Règimes de l'Assurance Maladie [SNIIRAM]), the hospital discharge summaries database (Programme de médicalisation des systèmes d'information [PMSI]) and the death registry (Centre d'épidemiologie sur les causes

médicales de décès [CEpiDC]) will provide access in collaboration with the Bordeaux PharmacoEpi research platform in pharmacoepidemiology.

9.2.1 Source population

variations thereof. All women registered for at least 12 months, with 1 of the 7 participating data sources during the study period, will be eligible as source population.

9.2.2 Study period

Since the marketing authorization of romosozumab was granted in the EU on 09 Dec 2019, the study period is expected to begin early in 2020. The study period will end at the most recent version of data that is available within each of the databases at the end of the study, expected 4 years after the study start date. Annual reports will be submitted for a total of 4 years. Upon the minimum sample size being reached as set out in Section 9.5, the comparative safety analysis will be conducted and reported as part of the following interim and/or final report/s. If the minimum sample size is reached before the end of the 4-year study period, the study will continue until the end of the study period to allow variability and better precision in the estimates of IR and HR.


9.2.3 Study population

The study population represents the indicated population for romosozumab in Europe as per the SmPC and therefore, will comprise of all women from the source population with severe OP who are dispensed or prescribed an OP medication of interest for the first time (new users) during the study period. They will also have been continuously registered in the data source for at least 12 months prior to the first recorded dispensing/prescription of the OP medication of interest and are at least 50 years of age on the date of the first dispensing/prescription of the OP medication of interest.

Osteoporosis medications of interest are romosozumab, ALN, risedronate, ibandronate, zoledronate, denosumab, and teriparatide and will be identified through specific codes in dispensation or prescription records. In order to identify new users, no prior use of the same study drug during the previous 12-month Baseline Period is allowed.

The date of the first dispensation or prescription within the study period that qualifies the user as a new user of 1 of the study drugs will be defined as the index date. Analyses will be conducted using a time-varying exposure strategy, where patients who switch to another index treatment (ie, to a different drug) over time contribute to the different index treatment arms/groups. This is This document canno represented in Figure 1.

Figure 1: Representation of patient eligibility and follow-up into different treatment cohorts



Note: "First prescription drug A" is the index date for a patient during exposure to drug A, and "First prescription drug B" is then the index date for the same patient when exposed to drug B.

Before the analysis is undertaken for each report, the RMM label used in each country will be checked. Should any country deviate from the EU-wide RMM, including but not limited to SmPC and RMMs, this will be reported to the EMA and the impact of this change will be discussed in the report.

9.2.4 Inclusion criteria

New users of romosozumab, ALN, risedronate, ibandronate, zoledronate, denosumab, and teriparatide will be identified. In order to identify new users, no prior use of the same study drug (eg, ALN) or the same drug class (eg, bisphosphonates) during the previous 12-month Baseline Period will be allowed. Prescriptions dispensations or claims for other study drugs, including other OP medications that are not of interest in the study, will be allowed during the Baseline Period in order to identify previously treated patients.

All the following inclusion criteria must be met for participants to enter the study:

- Women aged 50 years or older at the time of index therapy initiation
- At least 12 months of eligibility in the database before therapy initiation with continuous enrollment
- Severe OP, as identified by the presence of 1 or more fracture/s of any skeletal sites except face/skull/digit/s recorded in the year prior to therapy initiation
- No prior use of the same drug (or drug class) during the 12 months prior to therapy initiation

9.2.5 **Exclusion criteria**

Exclusion criteria include:

- hisdocu Dispensing, claim, or prescription of more than 1 study drug on the same date (ie, combination therapy)
 - Patients with a diagnosis of cancer (any except basal cell skin cancer) or Paget disease at any time before index date (ie, treatment initiation)

- User/s of the same drug/drug class in the year before index date

As the study proposes to focus on the approved indicated population for romosozumab, patients not meeting the EU label criteria will be excluded:

9.2.6

New users of OP medications will be followed for a maximum of 24 months from index therapy initiation (index date). Switching will be handled using a time-varying exposure strategy as depicted in Figure 1 above. Overlapping treatment with 2 or more OP drugs (except calcium/vitamin D supplements) for >1 month will result in censoring of the patient, as will reinitiation of a new treatment episode related to a previously prescribed treatment (reinitiation).

Two Follow-up Periods will be included for the estimation of SLIRs in each of the study drug cohorts separately; an Exposure-based Follow-up Period and a Fixed (first exposure carried forward) Follow-up Period.

For the exposure-based analysis, participants will be followed until the occurrence of the SI event of interest, discontinuation of the study drug of interest, switching or addition of any other OP medication (except calcium/vitamin D supplements), lost to follow-up, death, or end of the 12 months after therapy initiation. The total follow-up period is designed to cover a 12-month, post-initiation period in line with romosozumab administration per the SmPC.

For the Fixed Follow-up Period, the participants will be followed in their respective cohorts until lost to follow-up, SI events of interest, death, or end of the study period. This will be a maximum of 24 months following the index date, regardless of exposure status, cessation, addition of another OP medication (except calcium/vitamin D supplements) or switching. For the fixed follow-up analysis, the IR of SI events of interest will be reported at 6, 12, 18 and 24 months following the identified index dates for study drug initiation.

For the comparative safety analyses (Objective 3), patient characteristics (ie, confounders) will be reassessed and propensity scores recalculated at the beginning of each treatment episode to minimize time-varying confounding. Each treatment episode will therefore be treated as a new exposure period.

9.3 Variables 9,3.1

Exposure

Exposure to OP medications in each data source will be assessed according to the ATC classification system or other country and data source-specific coding system used for recording.

Osteoporosis medications of interest include:

1. Drug of interest:

- Romosozumab (ATC M05BX06) and,
- 2. Other OP medications specifically
 - ALN (ATC M05BA04) (primary active comparator)
 - Other oral bisphosphonates (ibandronate [ATC M05BA06] or risedronate [ATC M05BA07]) at doses indicated for OP treatment
- tions there of iv bisphosphonates (zoledronate [ATC M05BA08] or iv ibandronate [ATC M05BA06]) iensions of at doses indicated for OP treatment
 - Denosumab (ATC M05BX04) at the dose indicated for OP treatment
 - Teriparatide (ATC H05AA02)

All of the OP medications listed above will be analyzed for Objectives 1 and 2' (see Section 8).

Alendronate (ATC M05BA04) will be the active comparator in the comparative safety analyses (Objective 3).


Exposure to a study drug will commence on the index date, ie, date of the first dispensation or prescription for the study drug or record for an office-based administration without any record of study drug use during the Baseline Period. The end of exposure will be defined as the date of the last dispensation/claim for the study drug plus the calculated number of exposure days provided in the last prescription/dispensation based on the dispensed strength, package size and defined daily dose (DDD).

The recommended dose of romosozumab is 210mg (administered as 2 subcutaneous injections of 105mg each) once monthly for 12 months. Romosozumab 105mg solution for injection is delivered via a prefilled pen or prefilled syringe, each delivering 105mg of romosozumab in 1.17mL of solution (90mg/mL).

Based on the pharmacological profile of romosozumab, it is expected that the majority of romosozumab will be eliminated after 64 days and the drug effect is diminished for a refill gap exceeding 3 months. Treatment gaps of ≤ 90 days between drug utilization records for any of the study drugs will be allowed. This is consistent with previously published observational analyses focused on persistence with OP medications (Reyes et al, 2017).

Drug discontinuation will be defined as no dispensation/prescription during a 3-month period after the end of exposure, with end of exposure estimated as the date of the last prescription + the number of doses prescribed/dispensed in that last prescription. Stockpiling will not be considered (see Figure 2). Drug discontinuation will also be considered at the date when a concomitant second OP medication is added. this document

Figure 2: Construction of treatment episode/s for patient-level drug utilization, incidence rate/s, and comparative safety study



Any subsequent claim associated with a study drug administration after the discontinuation of that same drug (for longer than the established refill gap) will be classified as treatment reinitiation, and therefore excluded from all analyses

Treatment switches will be handled as follows:

- For Objectives 1 and 2, the analyses will be conducted at the treatment episode level as in Figure 2 above. For example, a user of denosumab who then switches to ALN will contribute first to the denosumab user, and then (after switching) to the ALN user cohort.
- For Objective 3 (comparative safety), follow up will start with the first prescription of either ALN or romosozumab, regardless of previous other OP drug use. A switch from romosozumab or ALN to any other OP drug will result in censoring. In contrast, switching from ALN to romosozumab or from romosozumab to ALN will be handled as a time-varying exposure, just like in Objectives 1 and 2.

9.3.2 Outcomes

<u>Primary outcome:</u> SHeading to hospitalization

Secondary outcomes

• Death due to SI, operationalized as either of:

In-hospital death with a diagnosis of infection during the same admission/episode

Recorded diagnosis of any infection followed by death in the subsequent month

This document

Outcome identification and validation

The proposed code list/s or algorithm/s for the identification of SI are fully detailed in

Death is identified directly through linkage to administrative records or mortality registries in the most of the proposed databases (CPRD through linkage to the Office of National Statistics: All SIDIAP through linkage to the administrative database of national inc. Helweg-Larsen, 2011]; and SNDS through linkage to the National Mortality Registries), but not all (see Table 1). Mortality has been previously validated in GePaRD and shown to be highly valid (positive predictive value [PPV] >97%) (Ohlmeier et al, 2016; Ohlmeier et al, 2015). All-cause mortality has been validated in IPCI (Netherlands) and HSD (Italy) in the context of previous PASS.

Database	Validity of SI	Validity of death	
Nationwide linked Danish registries (DK)	Yes	Yes (built in validation of civil registration system) (Madsen et al, 2003)	
HSD (IT)	No	Yes ^a	
IPCI (NL)	No guille	Yes ^a	
SIDIAP (ES)	<− Ne Ne	Yes	
GePaRD (DE)	No	Yes (Ohlmeier et al, 2016; Ohlmeier et al, 2015)	
SNDS (FR)	No No	Yes (source=national death registry)	
CPRD (UK)	Yes	Yes (specific death register)	

Table 1: O	Overview of outcome validation available with	n references
------------	---	--------------

CPRD=Clinical Practice Research Datalink; DE=Germany; DK=Denmark; ES=Spain; FR=France; GePaRD=German Pharmacoepidemiological Research Database; HSD=Health Search Database; IPCI=Integrated Primary Care Information Project; IT=Italy; NL=Netherlands; PASS=post-authorization safety study(ies); SI=serious infection; SIDIAP=Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària; SNDS=Système National Des Données de Santé

^a Available from the data owner based on other PASS-related activity in partnership with EU-ADR Alliance.

Where validations have not been done or have showed a low PPV (<75%), the Applicant in collaboration with the EU-ADR Alliance will conduct validation studies with a random sample of 250 cases per database. The validation studies will be implemented in parallel and will have no impact of the proposed study timelines. If this shows a low PPV (<75%), then all "potential" cases in the comparative safety analysis will be individually validated, and only confirmed ones will be included for analysis. This strategy has been recently implemented in similar PASS including EUPASS9117 (EU-ADR Alliance, 2017).

Details of the proposed validation studies are provided in Appendix 4.

9.3.3 Covariates (confounders and interaction terms)

9.3.3.1 Potential confounders

propensity score models. Key confounders have been identified a priori based on previous literature and recent research and are listed below. The final list of confounders included in the propensity score equation will be identified during the estimation of propensity scores using multivariable logistic regression equation (see details below) The set of variables are are

The set of variables are grouped into 4 main categories: general patient characteristics, SI risk factors, markers of OP severity, and use of other medications at baseline. This list will be refined following ongoing work on the identification of imminent fracture risk in the indicated population led by the Centre for Statistics in Medicine (University of Oxford), in collaboration with academic centers with access to data sources from Denmark, Spain, and the UK and a literature search of risk factors of SI.

Beyond the lists below, the final detailed code lists will be provided once access to the study data is available.

It must be noted that different data sources will have access to different variables and/or proxies for each of the confounders listed below. It is expected that primary care records will have easier access and more granularity on clinical measurements (eg, body mass index [BMI]), and laboratory values, whilst registers, hospital records and claims data will have richer data on healthcare resource use (eg, hospital contacts), hospital treatments (eg, surgical procedures or medical devices). Therefore, a combination of these will be used to capture as much detail as possible on each of the key risk factors below. Propensity scores will indeed be estimated for each data source separately to maximize the richness and granularity of each data source, and to capture as much information as possible on the key confounders prespecified below.

- General characteristics:
 - Socio-demographics age, sex, socio-economic status (where available)
 - Country of residence/database
 - Number of previous general practitioner (GP)/hospital contact/s in the year before index date
 - Number of ATC/British National Formulary (BNF) codes prescribed in the year before index date
 - Charlson comorbidity index (most recent as recorded in the year before index date)
 - Other (selected) comorbidities:
 - Liver failure/disease
 - Laboratory markers
 - White blood cell counts (total and subtypes as available)

- Serum creatinine 0
- Cholesterol 0
- Medical device use (as recorded in the year before index date)
 - Devices connected with CV procedures 0
 - 0 Devices connected with fracture healing
 - Devices connected with limited mobility 0
- variations thereof. SI risk factors - A final list will be defined with feedback from clinicians with expertise in the management of serious infectious disease. A preliminary list is provided here?

 - La in previous year) Land Anstory of chronic obstructive pulmonary disease History of any surgery in the year before index date History of chronic kidney disease History of liver failure/liver disease History of immunodee istory History of human immunodeficiency virus infection (HIV) and/or acquired immune deficiency syndrome (AIDS)
 - Previous history of SI events
- Markers of disease severity (risk factors for OP/fractures):
 - History of recorded OP at any time before index date
 - History of previous OP medication/s use
 - History of previous fracture/s: site/s (hip, vertebral, major osteoporotic, other/s), number of fracture/s, and time from most recent to index date
 - History of rheumatoid arthritis at any time before index date
 - History of eating disorder/s (anorexia nervosa, bulimia) at any time before index date
 - Use of inhaled respiratory glucocorticoids (ATC R03BA)
 - Use of systemic glucocorticoids (ATC H02AB): cumulative number of DDDs of prednisone equivalents prescribed in the year before index date
 - Previous use of other OP medications (ATC M05B) in the year before index date: type, number of therapies, and DDDs prescribed

- Previous use of prescribed vitamin D supplements (ATC A11CC01, A11CC03, A11CC04, A11CC05, A11CC06, A11CC20, and A11CC55) in the year before index date
- or variations thereof Previous use of prescribed calcium supplements (ATC A12AA01, A12AA02, A12AA03, A12AA04, A12AA05, A12AA06, A12AA07, A12AA08, A12AA09, A12AA10, A12AA11, A12AA12, A12AA13, A12AA20, and A12AA30) in the year before index date
- Previous use of prescribed calcium and vitamin D (concomitant) supplements (ATC A12AX) in the year before index date
- Use of medications associated with low bone mineral density/OP as prescribed in the year before index date
- Use of other medication/s associated with fall/s and/or fracture/s as prescribed in the year before index date
- Number of recorded fall/s in the year before index date
- Estimated absolute 5-year fracture risk score based on the Garvan nomogram (Bolland et al, 2011), recently tested by members of the EU-ADR Alliance
- Bone mineral density T-score recorded in the year before index date (if available) (Note: not to be included in the propensity score due to probable confounding by indication)
- Use of other medications at baseline: •
 - Use of any drugs: number of different ATC classes (ATC 4-digit groups) used in the year prior to cohort entry
 - Use of antineoplastic agents (ATC L01)
 - Use of immunosuppressants (ATC L04)
 - Use of lipid-lowering agents (ATC C10) at cohort entry
 - Use of oral antidiabetic agents (ATC A10B) at cohort entry
 - Use of antihypertensive drugs in the year prior to cohort entry: alpha blockers (ATC C02CA), beta-blockers (ATC C07), angiotensin-converting enzyme inhibitors (ATC C09A/C09B), angiotensin II inhibitors (ATC C09C/C09D), calcium channel blockers (ATC C08C)
 - Use of low-dose aspirin (ATC B01AC06) or clopidogrel (ATC B01AC04) in the year prior to cohort entry
 - Previous use of anticoagulants in the year prior to cohort entry: vitamin K antagonists (ATC B01AA), heparins (ATC B01AB), direct thrombin inhibitors (ATC B01AE), direct factor Xa inhibitors (ATC B01AF)
 - Previous use of OP medications (ATC M05B) in the year prior to cohort entry

- Polypharmacy: use of, for example, 5 or more medications from different therapeutic classes in the year prior to cohort entry.

Interaction/stratification terms The SI event/s rates (as in Objectives 1 and 2) will be provided stratified by key SI risk factors. John the IRs of SI events of interest will be calculated based on the 2 Follow-up Period. (exposure-based and fixed, as described in Section 0.2.5.5) accordance with the secondary objectives, stratification will be conducted based on the following baseline characteristics of each of the study cohorts:

- Age (on the index date)
- Prior use of OP medication: Prior OP medication use will be defined by at least 1 dispensation or claim for an OP medication other than study drug during the Baseline Period
- Previous history (prior year) of SI events

Further stratification variables will be defined to capture all relevant SI risk factors if requested and in agreement with the regulatory authorities. 3

9.4 Data sources

This study will be conducted using routinely collected data from different data sources that participate in the EU-ADR Alliance, with the addition of databases from the UK (CPRD GOLD), Germany (GePaRD), and France (SNDS).

These databases will provide representative clinical information as collected in routine clinical practice in different European healthcare settings.

The proposed databases have been selected based on their geographic location, the availability of longitudinal population-based data on drug utilization, and their experience in previous multi-database studies on both drug utilization and safety.

Seven countries from different European areas are included, in order to provide heterogeneous and representative data on the safety of romosozumab as well as ensuring sufficient statistical power for the study.

All analyses will be conducted in a federated manner using the tools previously validated and tested in a number of PASS completed by the EU-ADR Alliance.

All of the chosen databases comply with EU guidelines on the use of medical data for medical research and have been validated for pharmacoepidemiological research (Cazzola et al, 2011; Nug et al, 1999). All of the contributing data sources are listed under the ENCePP resources database (ENCePP Resources Database, 2019).

The confirmed participating databases will be HSD (Italy), IPCI (Netherlands), the nationwide linked Danish registries (Denmark), and SIDIAP (Spain), all of which form part of the stable structure of the EU-ADR Alliance, and additionally, CPRD (UK), GePaRD (Germany) and

was

Table 2: Overview of the considered databases

Table 2: Overv	iew of the cons	idered datab	ases			vailation	
Country	Netherlands	UK	Denmark	Italy	Spain	Germany	France
Name of the database	IPCI	CPRD	Nationwide linked Danish registries	HSD-Thales	SIDIAP	GePaRD	SNDS
Type of database	MR	MR	ADM	MR	MR	ADM	ADM
# active patients (millions)	1.2	5	5.8	1.5	5.8	25	66
Age categories	All	All	All	>15 years	>15 years	All	All
Date in	Yes	Yes	Yes	A Yes	Yes	Yes	Yes
Date out	Yes	Yes	Yes	Yes	Yes	Yes	No
Date death	Yes	Yes		0 37	Yes	Yes	Yes (mm/yyyy)
Prescriptions			Yes Drill				
Outpatient treatment/s	Yes (specialist incomplete)	Yes (specialist incomplete)		Yes (specialist incomplete)	Yes (specialist incomplete)	Yes	Yes (dates of prescription and dispensing)
Coding of drugs	ATC	BNF/Multilex	ATC	ATC	ATC	ATC	ATC
Dosing regimen	Yes	Xean Xean	No	Yes (incomplete)	Yes	No	Number of units and dosage dispensed
Outcomes	*0	9					
Hospitalizations	Yes	Yes (60%)	Yes	Yes	Yes (30%)	Yes	Yes
Outpatient diagnoses	Yes	Yes	Yes (hospital outpatient)	Yes	Yes	Yes (hospital outpatient)	No
Hospitalizations Outpatient diagnoses	canth						

the the 18 Jun 2020 OP0006

Table 2: Overview of the considered databases

Country	Netherlands	UK	Denmark	Italy	Spain	Germany	France
Coding of disease	ICPC	READ	ICD-10	ICD-9-CM	ICD-10 (ICD-9) for hospital diagnoses)	ICD-10_GM	ICD-10
Cause of death	No	From linked ONS death data (60%)	Yes (lag 2 years)	No	andanno	No	Yes, with a 2-to 4-year lag (only for 2013-2015 at present)

ADM=administrative; ATC=Anatomical Therapeutic Chemical; BNF=British National Formulary; CM=clinical modification; CPRD=Clinical Practice Research ia. seman me. .PC=Internation .s; SDIAPSister ACTIP Autoritation A Datalink; GePaRD=German Pharmacoepidemiological Research Database; GM=German modification; HSD=Health Search Database; ICD=International Classification of Diseases; ICD-10=ICD, revision 10; ICD-9=ICD, revision 9; ICPC=International Classification of Primary Care; IPCI=Integrated Primary Care Information Project; MR=medical records; ONS=Office for National Statistics; SIDIAP=Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària; SNDS=Système National Des Données de Santé

Confidential

thereof

IPCI DATABASE - NETHERLANDS

In 1992, the IPCI was started by the Department of Medical Informatics of the Erasmus University Medical Centre. The IPCI is a longitudinal observational database that contains data from computer-based patient records of a selected group of GPs throughout the Netherlands, who voluntarily chose to supply data to the database. Collaborating practices are located throughout the Netherlands and the collaborating GPs are comparable to other GPs in the country according. to age and gender. In the Netherlands, all citizens are registered with a GP practice, which forms the point of care and acts as a gatekeeper in a 2-way exchange of information with secondary care. The medical records of each patient can therefore be assumed to contain all relevant medical information including medical findings and diagnosis from secondary care.

The IPCI database is representative of the Dutch population regarding age and gender (Voordouw et al, 2004).

The database contains information on about 2.5 million patients. This is the cumulative number of patients who have ever been part of the dynamic cohort of registered patients. The International Classification of Primary Care (ICPC) is the coding system for patient complaints and diagnoses but diagnoses and complaints can also be entered as free text. Prescription data such as product name, quantity prescribed, dosage regimen, strength and indication are entered into the computer (Vlug et al, 1999). The National Database of Drugs, maintained by the Royal Dutch Association for the Advancement of Pharmacy, enables the coding of prescriptions, according to the ATC classification scheme recommended by the World Health Organization (WHO, 2019). Approval needs to be obtained for each study from the governance board.

HSD-ITALY

The Italian partner for the study will use the HSD, a longitudinal observational database that is representative of the Italian general population. The HSD was established in 1998 by the Italian College of General Practitioners (Filippi et al, 2005). The HSD contains data from computer-based patient records from a selected group of GPs covering a total of 1.5 million patients located throughout Italy. These GPs voluntarily agreed to collect data for the database and attend specified training courses. The database includes information on the age, gender, and identification of the patient and GP registration information, which is linked to prescription information, clinical events and diagnoses, hospital admission, and causes of death. All diagnoses are coded according to International Classification of Diseases, revision 9, clinical modification (ICD-9-CM). Drug names are coded according to the ATC classification system (WHO, 2019). To be included in the study, GPs must have provided data for at least 1 year and meet standard quality criteria pertaining to levels of coding, prevalence of well-known diseases, and mortality rates (Cricelli et al, 2003). The HSD has been used as a data source for a number of peer-reviewed publications on the prevalence of disease conditions, drug safety and prescription patterns in Italian primary care (Cazzola et al, 2011). Approval for use of data is This docur obtained from the Italian College of General Practitioners for each study.

NATIONWIDE LINKED DANISH REGISTRIES - DENMARK

The Danish National Health Service provides universal tax-supported health care, guaranteeing unfettered access to GPs and hospitals, and partial reimbursement for prescribed medications

(Schmidt et al, 2019). Accurate linkage of all registries at the individual level is possible in Denmark using the unique Central Personal Register (CPR) number assigned to each Danish tions thereof citizen at birth and to residents upon immigration (Schmidt et al, 2014). Data available on these patients can be linked to all registries. Dispensing data, recorded in the Danish National Prescription Registry (Pottegård et al, 2017) comprise of dispensing data from community pharmacies and contains information on name of the drug, ATC code, package identifier (strength and route of administration), and the date of refill. These data can be linked to the Danish National Patient Registry, which comprises information on admissions to Danish somatic hospitals, emergency rooms and outpatient clinics, diagnosis codes and procedures (Schmidt et al, 2015). These databases have been used in numerous studies and are proven valid for pharmacoepidemiological research. The study must be announced at the governance committee. All registries will be accessed on per-protocol basis at the servers of the data custodians: Danish Health Data Board or Statistics Denmark. and

SIDIAP DATABASE - SPAIN

The GPs play an essential role in the public healthcare system of Spain, as they are responsible for primary health care, long-term prescriptions and specialist and hospital referrals. The Spanish public health care system covers more than 98% of the population. The SIDIAP database comprises of electronic medical records (EMRs) of a representative sample of patients attended by GPs in Catalonia (North-East Spain), covering a population of more than 5.8 million patients (over 80% of the total of 7.5 million population of Catalonia) from 274 primary care practices with 3414 participating GPs. The SIDIAP data comprises the clinical and referral events registered by primary care health professionals (GPs and nurses) and administrative staff in EMRs, comprehensive demographic information, prescription and corresponding pharmacy invoicing data, specialist referrals, primary care laboratory test results, and hospital admissions and their major outcomes.

Health professionals gather this information using International Classification of Diseases, revision 10 (ICD-10) codes and structured forms designed for the collection of variables relevant for primary care clinical management, such as country of origin, sex, age, height, weight, BMI, tobacco and alcohol use, blood pressure measurements, and blood and urine test results. Only GPs who meet quality control standards can participate in the SIDIAP database. Encoding personal and clinic identifiers ensures the confidentiality of the information in the SIDIAP database. Recent reports have shown the SIDIAP data to be useful for epidemiological research (García-Gil Mdel et al, 2011).

Studies performed using SIDIAP data require previous approval by both the Scientific and the Ethics Committee.

CPRD GOLD - UK

The UK patients' data will be sourced from CPRD.

The CPRD (former GPRD) comprises of computerized records of all clinical and referral events in both primary and secondary care in addition to comprehensive demographic information, medication prescription data (coded using Gemscript codes), clinical events (coded using READ codes), specialist referrals, hospital admissions and their major outcomes in a sample of UK

hisdocu

patients. The prescription records include information on the type of product, date of prescription, strength, dosage, quantity, and route of administration.

Data from contributing practices are collected and processed into research databases. Quality checks on patient and practice level are applied during the initial processing. Patients with records showing ill-defined or non-continuous follow up, and missing or inconsistent registration information are excluded during this process. The CPRD aims to obtain data from the earliest possible data points meeting "Up to Standard" (corresponding to the date when data meet specified data entry and quality criteria in GP practices signed up to CPRD). After this date, the practice is considered to have recorded continuous data of sufficiently high quality for use in research.

Data are available for over 20 million patients, including over 5.2 million currently registered patients which is considered to be representative of the UK population.

GePaRD - GERMANY

The GePaRD consists of claims data from 4 German statutory health insurance providers covering approximately 25 million individuals throughout Germany. Cross-sectionally, GePaRD covers about 15 million individuals, which represents approximately 17% of the German population of 82 million inhabitants.

The GePaRD contains individual level information on demographic characteristics, hospitalizations (including admission diagnoses, main discharge diagnoses, and reason for discharge including death), outpatient physician visits, and outpatient drug dispensations for reimbursed products. While exact dates are provided for hospitalizations and outpatient drug dispensations, only the year and quarter are known for outpatient diagnoses. Drugs that are purchased over the counter are not contained in the database. With a few exceptions the same applies to medication administered in hospital. The acceptability of GePaRD for pharmacoepidemiological research has been assessed methodologically as well as by validation studies (Ohlmeier et al, 2016; Ohlmeier et al, 2015; Ohlmeier et al, 2014; Pigeot and Ahrens, 2008). Recently, GePaRD has been used for various types of pharmacoepidemiological studies including drug utilization studies and studies investigating the risks of drugs or vaccines (Schink et al, 2018; Schmedt et al, 2016a; Schmedt et al, 2016b; Schink et al, 2014).

In Germany, the utilization of health insurance data for scientific research is regulated by the Code of Social Law. All involved health insurance providers as well as the German Federal (Social) Insurance Office and the Senator for Science, Health, and Consumer Protection in Bremen as the responsible authorities, approved the use of GePaRD data for this study. Informed consent for studies based on GePaRD is not required by law, and according to the Ethics Committee of the University of Bremen, these studies are exempt from IRB review.

SNDS DATABASE - FRANCE

The SNDS database is the French nationwide healthcare insurance system database with individual anonymous information on all reimbursed outpatient claims linked to the national PMSI and the national death registry, using a unique national pseudonymized identifier. It currently includes 98.8% of the French population, more than 66 million persons from birth (or immigration) to death (or emigration), even if a patient changes occupation or retires.

The SNDS contains individual pseudonymized information on the following (Bezin et al, 2017; Tuppin et al, 2010):

- General characteristics: gender, year of birth, affiliation scheme, area of residence; deprivation status (CMU-c);
- Date of death for those concerned and (very soon) cause of death;
- tionsthereof Long-term disease (LTD, or ALD in French, and associated ICD-10 codes) with starting and ending dates. The LTD is mainly concerned with costly chronic diseases. The LTD registration is obtained at the request of a patient's practitioner and validated by the health insurance system physician. Once registered, patients receive full (ie, 100%) reimbursement for expenditure related to the LTD. The LTD information is specific for the diagnosis (very low risk of false positives), but not sensitive because not all patients with the disease are registered and benefit from LTD;
- Outpatient reimbursed healthcare expenditures: visits, medical procedures, nursing acts, physiotherapy, medical images, laboratory tests, drugs, medical devices, transport, sick leave with prescriber and professional caregiver information (medical or paramedical specialty, private/public practice), dates (prescription and dispensing), associated costs, and codes (but not the medical indication nor result);
- Hospital discharge summaries from the PMSI-1CD-10 diagnosis codes (primary, linked and associated diagnosis) for all private and public medical, obstetric and surgery hospitalizations, with the date and duration of hospitalization, medical procedures, and cost coding system, as well as most of the new costly drugs. The hospital discharge summary includes each department summary (eg, intensive care, then cardiology, then surgery). Primary diagnosis is the health problem that motivated the admission to the hospital. This is determined at hospital discharge. For patients hospitalized successively in several medical units, the primary diagnosis of the hospitalization, as well as all medical unit primary diagnoses, are generally taken into account to define the occurrence of an outcome in a pharmacoepidemiology study. A linked diagnosis can exist only if the primary diagnosis is a care procedure with a code Z of the ICD-10 classification (eg, chemotherapy session) for a chronic or LTD. It indicates the pathology at the origin of the care procedure.
- Nonhospital data are updated every month and hospital discharge summaries yearly at end of third quarter (03) for the previous year. Access to SNDS is regulated and needs approval from the National Institute of Health Data (Institut National Des Données de Santé [INDS]) and French data protection commission (Commission Nationale de l'Informatique et des Libertés [CNIL]).

Timing of data updates for the participating data sources

Different data sources update their data at different times of the year, with some datasets updating the information more frequently than others. To explain why data will be collected only between Apr and Jun, Table 3 shows how frequently and at what time of the year each data source is updated.

Table 3:	Overview of the timing of data updates from participating data
	sources

Data source (Country)	Periodicity of updates	Time of the year when updates are released	Data availability for each update		
SIDIAP (ES)	Yearly	Apr-May	End (31 Dec) of previous calendar year		
IPCI (NL)	Yearly (twice is possible)	Apr-May	Variable as GPs provide not all at same time		
CPRD (UK)	Monthly (linkage irregularly)	Every month	Variable as GPs provide not all at same time		
HSD (IT)	Every 6 months	Jun and Dec	End of previous calendar year (in Jun): up to Jun in Dec		
Nationwide linked Danish registries (DK)	Yearly	May	End (31 Dec) the previous year		
SNDS (FR)	Monthly (outpatient data)	Outpatient data: every month with a 6-month lag to be 98% complete in the database, and 2 years to be 100% complete.	Outpatient data: until month M-6		
	Yearly (inpatient data)	Inpatient data: year N-1 loaded in Sep-Oct of year N	Inpatient data: all outpatient stays ended year N-1		
GePaRD (DE)	Yearly	EDA authQ2/Q3	31 Dec of the second-to-last year (eg, 2017 date are available in Q3 2019)		

CPRD=Clinical Practice Research Datalink; DE=Germany; DK=Denmark; ES=Spain; FR=France; GePaRD=German Pharmacopidemiological Research Database; GP=general practitioner; HSD=Health Search Database; IPCI=Integrated Primary Care Information Project; IT=Italy; M=month; NL=Netherlands; Q=quarter; SIDIAP=Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària; SNDS=Système National Des Données de Santé

Note: Any changes to prescribing practice reflected in the databases may affect the results regarding bisphosphonates.

9.5 Study size

Since this study will be undertaken using routinely collected data, all patients meeting the eligibility criteria previously described will be included. Table 4 illustrates the feasibility counts including the number of incident users of each OP medication available in each of the contributing databases in the EU-ADR Alliance in 2016. These can be used to inform the availability of propensity-matched active comparator (ALN) and that of romosozumab users, which could potentially be similar to more advanced/costly therapies, such as teriparatide.

Although romosozumab is obviously not represented, market uptake is expected to be at least as high as teriparatide, probably not initially, but in subsequent years. As can be seen in Table 4, approximately 9,396 users of teriparatide have been identified in the contributing databases in the year 2016.

Table 4:Target population for the descriptive and drug utilization sections of
the proposed PASS - Numbers of new users of OP medications in
2016 in contributing databases

	Nationwide linked Danish registries (DK)	HS (IT)	IPCI (NL)	SIDIAP (ES)	GePaRD (DE)	SNDS (FR)	CPRD (UK)	TOTAL
ALN (ATC M05BA04)	15,000	2,578	2,108	11,508	8,622	25,000	7,852	72,668
All oral bisphosphonates (M05BA04, 06, or 07)	15,100	3,649	2,529	11,690	12,221	65,000	8,645	118,834
Zoledronate (ATC M05BA08)	6,800	22	112	-	165	30,000	62	37,161
Denosumab (ATC M05BX04)	2,100	417	529	4,364	2:356	38,000	410	48,176
Teriparatide (ATC H05AA02)	680	174	25	T,551	55	6,900	11	9,396

ALN=alendronate or alendronic acid; CPRD=Clinical Practice Research Datalink; DE=Germany; DK=Denmark; ES=Spain; FR=France; GePaRD=German Pharmacoepidemiological Research Database; HSD=Health Search Database; IPCI=Integrated Primary Care Information Project; IT=Italy; NL=Netherlands; OP=osteoporosis; PASS=post-authorization safety study(ies); SIDIAP=Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària; SNDS=Système National Des Données de Santé

These figures demonstrate the capabilities of the proposed consortium and data sources to capture a sufficient sample of patients in the considered study drug groups. Based on the above feasibility, we suggest that iv therapies (eg, zoledronate) will not be identified in the proposed study. Consequently, this observation will not impact the romosozumab sample as romosozumab will be commercialized as a subcutaneous preparation, similar to denosumab or teriparatide, which are well represented in the table above.

It is expected that all of the contributing databases will reliably collect information on the proposed SI events, as these will most likely lead to hospital admissions. Both primary and secondary care databases will therefore be able to identify all of the proposed outcomes. The 2 primary care databases with linkage to hospital inpatient data (SIDIAP and CPRD) will be useful to confirm the outcomes and perform any sensitivity analyses on hospital records data if needed. For more details about the outcome ascertainment algorithms and their validity, refer to Section 9.6.

Since romosozumab has yet to be launched, the sample size needed has been calculated by considering different levels of assumed IRs of SI events, instead of using power. Table 5 shows the number of romosozumab users and comparator users needed to obtain an alpha risk of 0.05 with 90% power in a 1:3 matched cohort analysis for different scenarios of incidence of SI events and HR.

The range of incidence of SI events has been defined based on IRs identified in the clinical studies. The results of this analysis showed a range from 1.0 to 2.5 per 100 person-years.

The range of HR has been defined based on results from SI safety data from study 20070337 (FRAME). These results show a potential excess risk of SI in romosozumab-treated subjects with magnitude ranging from zero to 2.13 (HR=1.49 [95% CI: 1.04, 2.13]). The study will thus be powered to provide additional confidence that, in those patients who receive romosozumab on label, there is no greater risk than that already characterized by study 20070337 (FRAME), using a margin of 2.2.

The number of participants needed will increase with decreasing incidence of the safet vevent and with decreasing HR. Although all patients eligible in the proposed data sources will be included, the natural consequence of this is that lower risk scenarios will result in a delayed conclusion of the study. Conversely, high risk scenarios defined by high incidence of SI events and high attributable risk, would result in a swift analysis: indeed, the worst-case scenario of IRs of 2.5 per 100 person-years and a 2.2-fold relative increase in risk would only require 900 romosozumab users (and 2,700 users of the active comparator).

Assumed incidence*	1	.0	1.	.5	2.5			
HR (upper limit 95% CI)	Romo	Comp	Romo	Comp	Romo	Comp	Romo	Comp
2.2	2,300	6,900	1,500	4,500	1,150	3,450	900	2,700
2.0	2,950	8,850	1,950	5,850	1,450	4,350	1,150	3,450
1.8	4,100	12,300	2,700	8,100	2,050	6,150	1,650	4,950
1.6	6,350	19,050	4,250	12,750	3,200	9,600	2,550	7,650
1.5	8,550	25,650	5,700	17,100	4,250	12,750	3,400	10,200
1.4	12,400	37,200	8,250	24,750	6,200	18,600	4,950	14,850
1.3	20,400	61,200	13,600	40,800	10,200	30,600	8,150	24,450
1.2	42,150	126,450	28,100	84,300	21,100	63,300	16,850	50,550

Sample size needed under different scenarios of incidence and HR, Table 5: with matching romo:comp is 1:31

CI=confidence interval; Comp=comparator; HR=hazard ratio; Romo=romosozumab; SI=serious infection


Note: This table shows the number of romo and comp users needed to obtain an alpha risk of 0.05 with 90% power in a 1:3 (romo:comp) matched cohort analysis for different scenarios of incidence of SI events and HR, where the true risk is 1,0 and 0% dropout.

- The calculation of the expected time to achieve sample size was based on: 1. The anticipated timing of the diff 1. The anticipated timing of the different commercial launches in each European country.
 - 2. The number of patients expected from each country assessed using an evaluation of epidemiologic data, number of patients currently treated post fracture and the number of patients treated with the anabolic agent teriparatide.

3. The assumption that local reimbursement criteria will allow the use of romosozumab in the indicated population.

Based on the assumed incidence and hazard ratio, the sample size is expected to be achieved at the study. **9.6 Data management** The EU-ADR Alliance works in a final study of the study o

locally, and pooling of aggregated data is done on a remote research environment (RRE) (see Figure 3 for overview).





ATC= Anatomical Therapeutic Chemical; ID=identifier

Due to the different database characteristics and coding schemes it is not possible to use 1 single data extraction algorithm for all the databases. To reconcile differences across terminologies, a shared semantic foundation will be built for the definition of events under study using the recently developed CodeMappe. A multi-step and iterative process for the harmonization of event data will be set up. his docume

The sequential steps of this process are briefly described below:

All events/outcomes have been ascertained using a list of agreed ICD (Denmark, France, The proposed lists of codes have been previously created and were validated for a previous study [EUPASS9117] following a number of steps: 1. Clinical definition;

- 2. Preliminary list of concept identifiers using Unified Medical Language System[®] (UMLS[®]) Metathesaurus Browser;
- 3. Addition of codes found after literature review of validated lists of codes for each of the study outcomes in each of the databases; and
- 4. Consensus with academic partners involved in the management and analysis of each of the data sources. As coding might change over time, relevant codes might be updated during the course of the project. Harmonization of these code lists will take place between databases by comparison of population-based age and sex specific IRs, according to standard quality assurance procedures in the EU-ADR Alliance (see below).

The sets of codes proposed based on these principles and used in previous studies will be further discussed with each of the academic partners and mapped to the newly incorporated data sources (Germany and France) during the first months of the study and before data extraction.

Identification of UMLS concepts 9.6.1

A UMLS concept is identified by a Concept Unique Identifier (CUI) and describes a single medical notion that can be expressed using different synonyms (terms). For each event, a medical definition will be created and based on such a definition, relevant UMLS concepts are identified and projected into the database-specific terminologies. In addition, for those databases where free text is available, the labels of the codes are considered for free text search of the events.

Definition of data extraction algorithm 9.6.2

Based on the relevant diagnostic codes and key words (for free text search), a data extraction algorithm will be constructed for each event based on the consensus of the data providers. This data extraction algorithm will then be implemented by all databases.

Event data extraction 9.6.3

Subsequently, each database extracts data locally and transforms them into a simple common data model, ie, standardized patient, drug, and event files linkable via a patient unique identifier.

Benchmarking of incidence rates of events

60⁰⁰ F For each endpoint and covariate, database-specific IRs will be benchmarked using Jerboa[®]; scripts will be generated by Erasmus MC. The observed IRs are compared with IRs estimated from previous database studies and literature. Outliers are identified and further investigated in an iterative manner.

This multi-step process has been used successfully in several other European multi-database projects. It maximizes the involvement of the data providers in the study by utilizing their knowledge on the characteristics and the process underlying the data collection.

After completion of harmonization, output tables for calculation and analysis of study endpoints will be created by the local data processors using the following steps (see Figure 4).

Figure 4: Process to be followed by local data processors



9.6.4 **Data elaboration**

A standardized Jerboa[©] script and instructions will be created by Erasmus MC to create the study-specific output tables. This will be developed in Jerboa (JAVA) by Erasmus MC and double-coded independently in SAS (version 9.4) by Aarhus. Either of these 2 versions will be used to "curate" the extracted data in the different databases.

9.6.5 Missing data

Since the underlying data represent attended medical care, it is assumed that absence of information of clinical events means absence of that condition. Lack of information on smoking, and alcohol use may occur, but this is unlikely differential. These will be binarized as "current smoker" or "heavy alcohol drinker" where data available suggests this in the year before index date, and assume participants are not smokers or heavy drinkers otherwise. This will help harmonize with hospital EMRs/administrative databases where no measurement of smoking/drinking is available.

9.6.6 Data sharing

A study-specific folder on the central Octopus RRE will be used to analyze the output provided by Jerboa[®]. These output files will contain only anonymized de-identified data that will be shared in the RRE where members will have a secure and restricted access and where data will be analyzed. SAS, version 9.4, will be used for post-processing of data. Small cell counts will be masked as required by local regulations.

The French and Danish data cannot be shared in the RRE and will therefore be analyzed locally after transformation using Jerboa[©] and/or equivalent (double-coded) SAS script. Findings will then be pooled in a meta-analysis.

9.7 Data analysis

ions thereo The proposed comparative safety analysis aims to assess whether in women with severe OP at high risk for fracture and no history of MI or stroke (as per proposed SmPC), treatment with romosozumab is associated with an increased risk of SI compared to users of ALN similar to the indicated population for romosozumab in Europe as per the SmPC and with similar baseline characteristics.

Numerous previous studies, including some conducted by the EU-ADR Alliance in similar indication and with similar outcomes (EUPASS9117), have demonstrated the feasibility and robustness of the proposed multi-database multinational real world comparative safety approach (EU-ADR Alliance, 2017). All analyses will be double-coded in 2 different statistical packages by 2 different statisticians at Oxford before sharing analytical programs with the different partners for analysis.

9.7.1 **Statistical elements**

Data analysis of the descriptive study component 9.7.1.1

9.7.1.1.1 SI incidence rates

For the analysis which determines the IR of each SI event of interest for each OP medication, the following calculations will be performed. In the case of Scenario 2 (see below), IRs of patients with SI events of interest will be reported as well.

Scenario 1: follow-up per drug exposure

IR of SI events of interest

number of events among patients in the study drug cohort number of exposed person – years at risk for the study drug cohort

Scenario 2: follow-up per first exposure carried forward

IR of SI events of interest

number of events among patients in the study drug cohort number of exposed person – years at risk for the study drug cohort

IR of patients with SI events of interest

number of patients with event of interest in the study drug cohort number of exposed person — years at risk for the study drug cohort

Incidence rates and 95% CIs will be calculated for each study drug cohort (as defined in Section 9.3.1) using a Poisson model. If there is overdispersion, a negative binomial model will be used instead. The IR will be reported for prespecified intervals of 6, 12, 18, and 24 months after treatment indexes in Scenario 2. These rates will be presented and reported annually, and

the number of patients and person-years at risk will be cumulative, such that the SI IRs reported here of variations thereof after the first year following launch will include both newly identified patients in addition to all patients identified in earlier years.

9.7.1.1.2 Stratified SI incidence rates

For each study drug exposure cohort, the SI IRs and 95% CIs will be stratified by the variables presented above in Section 9.3.3.2.

Comparative safety analyses

Propensity score matching

Propensity scores represent the probability that a given patient will receive the drug of interest (romosozumab) based on her baseline demographics and clinical characteristics specified in Section 9.3.3. This probability will be estimated using a multivariable logistic regression equation.

Propensity score matching reduces confounding by indication by producing comparable groups of patients in terms of observed confounders. In the proposed study, it is expected that romosozumab users will have high fracture risk as per the proposed label. Key features to be added in the propensity score equation will therefore include predictors of fracture as well as SI risk factors. Previous analyses of primary care (Hippisley-Cox et al, 2017) and of health register data around Europe (Rubin et al, 2018) have demonstrated the richness and detail of risk factors recorded in the proposed real-world data sources. In addition, ongoing work by the Centre for Statistics in Medicine in Oxford has confirmed this for the indicated population of interest, ie, women with OP and/or who initiate OP medication in clinical practice settings. All the identified risk factors in these will be included in the proposed logistic regression for propensity score estimation.

Patients using romosozumab will be matched to up to 3 users of ALN with a caliper width of 0.20 standard deviations (SDs) on the logit of the propensity score (Austin, 2011). Caliper matching is a strategy where only romosozumab users with "comparable" matches are kept in the analysis, whilst those with matched controls outside of the pre-established level of SD are excluded to minimize confounding. This is state-of-the-art methodology to minimize confounding by indication in pharmacoepidemiology and has been shown to replicate findings from randomized controlled trials in different settings (Strauss et al, 2019). An active comparator new user study design approach will be used (Lund et al, 2015).

Balance between the propensity-matched cohorts will be checked using absolute standardized mean differences. A difference ≥ 0.1 will show that a variable is unmatched between romosozumab users and the comparison OP medication. In this scenario, the propensity score model will be respecified and re-estimated and the balance will be rechecked. Should this strategy fail, double-adjustment (ie, further adjustment for imbalanced variables) to adjust for any potential imbalances after matching, as recommended by Nguyen et al (2017).

Survival analysis

Cox regression models stratified by matched sets will be used to calculate HRs and 95% CIs for each of the SI safety endpoints (hospitalization, death due to infection) according to drug

hisdocu

exposure in the propensity-matched cohorts. These analyses will be conducted "per treatment episode" as described above.

Adentified (in Additional Addition with a BMD measurement in the 12 months prior to treatment commencement. Should sufficient patients meet this criterion, a subgroup analysis will be performed in patients with clinically severe osteoporosis to complement the comparative safety of romosozumab.

Negative control outcomes

Cox regression models stratified by matched sets will also be used to calculate HRs and 95% CIs for a prespecified list of negative control outcomes. The definition of a negative control outcome is an outcome upon which the treatment and comparator are not expected to have an effect. The negative controls to be used in this analysis will be agreed with academic clinicians and provided in advance before comparative analyses are conducted. A preliminary and non-exhaustive list of potential negative control outcomes are listed here for illustrative purposes:

- Hernia repair surgery
- Inguinal hernia
- Road traffic accident
- Shoulder tendonitis/rotator cuff disease
- Knee osteoarthritis
- Hand osteoarthritis

Should the Cox regression analysis of more than 5% of the negative controls produce significant results, 3 additional analyses will be conducted to assess the effects of potential biases related to insufficient control for confounding/channeling bias: (i) empirical calibration using negative control outcomes; (ii) SCCS, and (iii) instrumental variable analysis.

Empirical calibration using negative control outcomes

iations thereof The obtained estimates from the analyses above will be used to empirically calibrate the HRs obtained from the primary propensity-matched analysis, as proposed by Schuemie et al (2018). This will provide a readjusted risk estimate of comparative SI safety after accounting for unobserved confounding.

SCCS

A SCCS will be undertaken. This method uses data only for the cases (ie, patients who have had an outcome) and assesses whether there is an elevated risk during time windows of exposure to the drug of interest (Petersen et al, 2016). The SCCS controls for all time fixed confounders, including unobserved ones.

Whilst this analysis does not assess at the whole population level, it will determine where the patient's outcome was more likely to occur before or after treatment and may support results sug, found in the Cox regression.

Instrumental variable analysis

Instrumental variable analyses based on physician prescription preference will be used. Under certain assumptions, instrumental variable analyses can account for residual confounding related to unmeasured variables. Instrumental variable analyses rely on the existence of an instrument, a variable that is strongly associated with the exposure of interest, but not associated with patient confounders and not directly associated with the outcome. Physician preference for the use of the study drug (ie, romosozumab) will be estimated using the previous 10, 20, and 50 prescriptions of OP medications at the prescriber level. Falsification tests will be used as diagnostics for the testable assumptions (Ali et al, 2014). 1) an association between the instrument (physician prescription preference) and the actual exposure will be tested using logistic regression modelling; and 2) the expected lack of association between the instrument and all the available confounders will be tested by measuring the standardized mean difference vs the estimated physician prescription preference.

Quality control 9.8

This study has been designed and shall be implemented and reported in accordance with the Guidelines for good pharmacoepidemiology practices of the International Society for Pharmacoepidemiology (ISPE, 2015), the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (von Elm et al, 2008), and with the ethical principles laid down in the Declaration of Helsinki.

This study is fulfilling the criteria of a "European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) study" and follows the "ENCePP Code of Conduct" (2018).

All programs will be programmed according to agreed coding standards and will be validated by double programming or source code review with second programmer involvement.

STATA version 15.1 (StataCorp, College Station, Texas, USA) and R (version 3.2.3, the R Foundation for Statistical Computing) will be used for statistical analysis.

9.9 Limitations of the research methods

This study is non-interventional and as such has several important limitations.

Selection bias is not an issue in this study since the study is based on electronic health care records and does not require active consent of participants. Therefore, lack of participation is not an issue. Selection bias might however arise if data are missing for some confounders (eg smoking or BMI) if the analyses are limited to a complete case. This binarizing as "current smoker" and " in primary care databases or based on the existence/absence of a record of smoker or alcohol addiction diagnoses in all the proposed data sources.

Information bias

Information bias may occur by not measuring correctly exposure, outcomes, or covariates.

With regards to exposure, misclassification may occur due to the patient not fulfilling the prescription (primary nonadherence) or in relation with noncompliance. Hence, an overestimate of utilization of romosozumab and other OP medications can happen, which would potentially lead to non-differential misclassification.

In parallel, misspecification of the risk window based on the construction of treatment episodes could lead to information bias. The effect of such potential misspecification will be addressed in sensitivity analyses where different refill gaps (<90, 90 and 180 days) will be used to define treatment episode duration.

Lack of recording (ie, incompleteness) of safety events may lead to misclassification of the safety endpoints.

Validation of the outcomes in all datasets has previously been addressed in Section 9.3.2.

Confounding

Due to the observational design chosen, causality in the observed associations will not be established. Instead, associations between drug use and risks will be assessed. As confounding by indication (with romosozumab users most likely to suffer more severe OP) will likely produce differences in baseline characteristics between romosozumab and other drug users, the study will use several methods to deal with confounding:

1. Restriction: comparative studies will be conducted only in persons in line with the label to restrict the population to those who would be prescribed romosozumab according to the label.

Matching: for the comparative studies, the study will use propensity score matching to minimize confounding related to all observed confounders.

- 3. Adjustment: the study will adjust for all covariates that remain imbalanced (standardized mean difference >0.1) after propensity score matching.
- 4. Sensitivity analysis: negative control outcome analyses will be used to identify any residual unobserved confounding in the propensity-matching analyses. If this analysis suggests the

hisdocu

presence of relevant unresolved confounding, then 3 additional analyses will be used to minimize the impact of any resulting bias, including empirical calibration, SCCS, and Variations thereof instrumental variable analyses. These are detailed in the previous section (Section 9.7.1.1.2).

9.10 Other aspects

Not applicable

10 **PROTECTION OF HUMAN SUBJECTS**

This PASS is a non-interventional (observational) study in compliance with the definition of non-interventional study provided in the 2017 Guideline on Good Pharmacovigilance Practice (GVP): Module VIII – post-authorisation safety studies, revision 3 (EMA/813938/2011, Rev 3, 2017) and in the ICH guideline of Pharmacovigilance Planning (ICH, 2004), *I*

This PASS will use secondary data collection and does not pose any risks for patients.

For this study, participants from 7 different European member states will process individual data as collected in national electronic health record databases in compliance with all applicable national and European regulation as well as with ethical and regulatory issues including those on privacy.

All of the databases used in this study are already used for pharmacoepidemiological research and have a well-developed mechanism to ensure that European and local regulations dealing with ethical use of the data and adequate privacy control are adhered to.

In agreement with these regulations, rather than combining person level data and performing only a central analysis, local analyses will be run, which generate non-identifiable data with less information that will be pooled across databases.

The output files will be stored in a central RRE held by Erasmus MC. These output files do not contain any data that allow identification of patients included in the study. In fact, each record is completely anonymous and does not contain any identifier key. Starting from this, the RRE implements further security measures in order to ensure a high level of stored data protection, according with the article 34 of legislative decree 196/2003 and article 22 of Regulation (EC) 45/2001.

The PASS will be registered in the ENCePP EU Post-Authorization Study (PAS) Register.

In addition, ascientific advisory committee consisting of external experts will be constituted to guarantee scientific soundness of the study and also to follow-up on the progress and the appropriate conduct of the study. The members of the scientific advisory committee will be involved in review of the data and preparation of the reports (yearly and final). this document

11 MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE DRUG REACTIONS

According to the most recent guidelines for good PV practice (EMA/813938/2011, Rev 3), there is no requirement for expedited reporting of adverse drug reactions from studies with secondary use of data (such as electronic health care databases).

All the identified adverse events related to the study outcomes will be summarized in the interim and final study report, which will consist of fully de-identified data. Therefore, it is not possible to assess the causality of individual cases.

There will be no reporting of adverse events/reactions for this study. The study outcomes will be provided in the study interim and final reports in aggregate tables.

12 PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS

Interim reports of descriptive statistics about the incidence and risk of SI associated with the use of romosozumab in comparison with other available OP medications will be provided in yearly increments. An interim comparative report will be submitted in year 3 after the beginning of the study and the final study report in year 4 after the beginning of the study.

In addition, dissemination activities will be undertaken including articles in scientific journals, and presentations at conferences. Publications will be developed according to UCB policies and authorship will be determined in accordance with the International Committee of Medical Journal Editors (ICMJE) guidelines.

In order to allow national competent authorities to review the results and interpretations to be published in advance, the MAH will communicate with the Agency and the competent authorities of the Member States where the product is authorized, the final manuscript of the article within 2 weeks after first acceptance for publication.

13 REFERENCES (AVAILABLE UPON REQUEST)

Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastrolenterology and Hepatology. 2007;5(9):1070-5.

Ali MS, Uddin MJ, Groenwold RH, Pestman WR, Belitser SV, Hoes AW, et al. Quantitative falsification of instrumental variables assumption using balance measures. Epidemiol. 2014;25(5):770-2.

Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150-61.

Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954-62.

Bolland MJ, Siu AT, Mason BH, Horne AM, Ames RW, Grey AB, et al. Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res.

Cricelli C, Mazzaglia G, Samani F, Marchi M, Sabatini A, Nardi R, et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med. 2003;25(3):254-7.

of the recording of 30 common childhood conditions in the Doctor's Independent Network and General Practice Research Databases. Health Stat Q. 2004:2:21-30.

EMA/813938/2011, Rev 3: Guideline of good pharmacovigilance practices (GVP). Module VIII - post-authorisation safety studies (Revision 3) (EMA). 2017. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-goodpharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3 en.pdf. Accessed on 25 Jan 2020.

EMA/95098/2010, Rev 7: Guide on methodological standards in pharmacoepidemiology (Revision 7). The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). 2010. Available from

http://www.encepp.eu/standards and guidances/documents/ENCePPGuideonMethStandardsinP E_Rev7.pdf. Accessed on 25 Jan 2020.

EU-ADR Alliance. European Program of Post-Authorization Safety Studies for Protelos[®]/Osseor[®] through EU-ADR Alliance: RMM Analyses (part of Final Report). 23 Nov 2017. Available from:

http://www.encepp.eu/encepp/openAttachment/studyResult/23300. Accessed on 25 Jan 2020.

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). ENCePP Resources Database. 2019. Available from:

www.encepp.eu/encepp/resourcesDatabase.jsp. Accessed on 25 Jan 2020.

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Code of Conduct. Por scientific independence and transparency in the conduct of pharmacoepidemiological and pharmacovigilance studies (Revision 4). 2018. Available from: http://www.encepp.eu/code of conduct/documents/ENCePPCodeofConduct.pdf. Accessed on 25 Jan 2020.

Filippi A, Vanuzzo D, Bignamini AA, Mazzaglia G, Cricelli C, Catapano AL. The database of Italian general practitioners allows a reliable determination of the prevalence of myocardial infarction. Ital Heart J. 2005;6(4):311-4.

García-Gil Mdel M, Hermosilla E, Prieto-Alhambra D, Fina F, Rosell M, Ramos R, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care. 2011;19(3):135-45. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health. 2011;39(Suppl 7):26-9.

lations thereof. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.

Holland-Bill L, Xu H, Sorensen HT, Acquavella J, Svaerke C, Gammelager H, et al. Positive predictive value of primary inpatient discharge diagnoses of infection among cancer patients in the Danish National Registry of Patients. Ann Epidemiol. 2014;24(8):593-7.

International Council for Harmonisation (ICH). Guideline of Pharmacovigilance Planning. Technical Requirements for Registration of Pharmaceuticals for Human Use (E2E), 2004. Available from: https://database.ich.org/sites/default/files/E2E Guideline.pdf. Accessed on 25 Jan 2020.

International Society of Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiology practices (GPP) (Revision 3). Jun 2015. Available from: https://www.pharmacoepi.org/resources/policies/guidelines-08027 Accessed on 25 Jan 2020.

Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Care & Research. 2006;55(1):19-26.

Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: Historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221-8.

Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: A comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003;56(2):124-30.

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412-20.

Nguyen TL, Collins GS, Spence J, Daurès JP, Devereaux PJ, Landais P, et al. Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol. 2017;17(1):78.

Ohlmeier C, Langner I, Garbe E, Riedel O. Validating mortality in the German Pharmacoepidemiological Research Database (GePaRD) against a mortality registry. Pharmacoepidemiol Drug Saf. 2016;25(7):778-84.

Ohlmeier C, Langner I, Hillebrand K, Schmedt N, Mikolajczyk R, Riedel O, et al. Mortality in the German Pharmacoepidemiological Research Database (GePaRD) compared to national data in Germany: results from a validation study. BMC Public Health. 2015;15:570.

Ohlmeier C, Frick J, Prütz F, Lampert T, Ziese T, Mikolajczyk R, et al. Use of routine data from statutory health insurances for federal health monitoring purposes. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(4):464-72.

Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19-26.

rigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf. 2008;17(3):215-23. Pottegård A, Schmidt SA, Wallach-Kildemoes H, Sørensen LTT T resource profile: The Danish Nation 17

2017;46(3):798-798f.

Reyes C, Tebe C, Martinez-Laguna D, Ali M, Soria-Castro A, Carbonell C, et al. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int. 2017;28(10):2997-3004.

Rubin KH, Möller S, Holmberg T, Bliddal M, Søndergaard J, Abrahamsen B. A new Fracture Risk Assessment Tool (FREM) based on public health registries. Bone Miner Res. 2018;33(11):1967-79.

Schink T, Kollhorst B, Varas Lorenzo C, Arfè A, Herings R, Lucchi S, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018;13(9):e0203362.

Schink T, Holstiege J, Kowalzik F, Zepp F, Garbe E. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine. 2014;32(6):645-50.

Schmedt N, Kollhorst B, Enders D, Jobski K, Krappweis J, Garbe E, et al. Comparative risk of death in older adults treated with antipsychotics: A population-based cohort study. Eur Neuropsychopharmacol. 2016a;26(9):1390-400.

Schmedt N, Jobski K, Kollhorst B, Krappweis J, Rüther E, Schink T, et al. Treatment patterns and characteristics of older antipsychotic users in Germany. Int Clin Psychopharmacol. 2016b;31(3):159-69.

Schmidt M, Schmidt SA, Adelborg K, Sundbøll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563-91.

Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, quality, and research potential. Clin Epidemiol. 2015;7:449-90.

Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-9.

Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci USA. 2018;115(11):2571-7.

Strauss V, Prats-Uribe A, Berencsi K, Carr A, Judge A, Silman A, et al. Propensity score stratification and inverse probability weighting compared to surgical randomized clinical trial results in device epidemiology. Pharmacoepidemiol Drug Saf. 2019;28(Suppl 2):79.

Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58(4):286-90.

Van Staa TP, Abenhaim L. The quality if information recorded on a UK database of primary care records: A study of hospitalization due to hypoglycemia and other conditions. Pharamacoepidemiol Drug Saf. 1994;3(1):15-21.

Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, et al. Postmarketing surveillance based on electronic patient records: The IPCI Project. Methods Inf Med. 1999;38(4-5):339-44.

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbrouche JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-9.

Voordouw AC, Sturkenboom MC, Dieleman JP, Stijnen T, Smith DJ, van der Lei J, et al. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. JAMA. 2004;292(17):2089-95.

Wentzell N, Schink T, Haug U, Ulrich S; Niemeyer M, Mikolajczyk R. Optimizing an algorithm for the identification and classification of pregnancy outcomes in German claims data. Pharmacoepidemiol Drug Saf. 2018;27(9):1005-10.

World Health Organization Collaborating Centre for Drug Statistics Methodology. ACT/DDD Index 2019. Available from: https://www.whocc.no/atc_ddd_index/. Accessed on 25 Jan 2020.

This document cannot be used to support any man

5.

APPENDIX 1. LIST OF STAND-ALONE DOCUMENTS

	Document reference number	Date	Title List of Stand-Alone Documents ENCEPP Checklist for Study Protocols List of Diagnosis Codes for Study Outcomes Validation Process for Study Outcomes
1	Appendix 1	28 Jan 2020	List of Stand-Alone Documents
2	Appendix 2	28 Jan 2020	ENCEPP Checklist for Study Protocols
3	Appendix 3	28 Jan 2020	List of Diagnosis Codes for Study Outcomes
4	Appendix 4	28 Jan 2020	Validation Process for Study Outcomes
mentcanne	the used to support	any marketing authoritatic	List of Diagnosis Codes for Study Outcomes Validation Process for Study Outcomes

APPENDIX 2. ENCEPP CHECKLIST FOR STUDY PROTOCOLS

Study title:

EU PAS Register[®] number: Study reference number (if applicable):

Stu	ly title:				
	PAS Register [®] number: ly reference number (if applicable):				Notion
Sect	ion 1: Milestones	Yes	No	N/A	Section
1.1	Does the protocol specify timelines for			at	
	1.1.1 Start of data collection ¹	\boxtimes			6
	1.1.2 End of data collection ²	\boxtimes	B		6
	1.1.3 Progress report(s)	\boxtimes	2		6
	1.1.4 Interim report(s)	$\boxtimes^{(0)}$			6
	1.1.5 Registration in the EU PAS Register $^{ m extsf{8}}$				6
	1.1.6 Final report of study results.				6

Comments:

The final timelines will depend on the date of the protocol approval

<u>Sect</u>	tion 2: Research question	Yes	No	N/A	Section Number
2.1	Does the formulation of the research question and objectives clearly explain:	\boxtimes			7 & 8
	2.1.1 Why the study is conducted? (e.g. to address an important public health concern, a risk identified in the risk management plan, an emerging safety issue)	\boxtimes			7
	2.1.2 The objective(s) of the study?	\boxtimes			8
	2.1.3 The target population? (i.e. population or sub- group to whom the study results are intended to be gen- eralised)	\boxtimes			9.2.3
	2.1.4 Which hypothesis(-es) is (are) to be tested?		\boxtimes		
c ^r	2.1.5 If applicable, that there is no <i>a priori</i> hy- pothesis?				

This docut ¹ Date from which information on the first study is first recorded in the study dataset or, in the case of secondary use of data, the date from which data extraction starts.

² Date from which the analytical dataset is completely available.

<u>Sec</u> t	ion 3: Study design	Yes	No	N/A	Section Number	
3.1	Is the study design described? (e.g. cohort, case-con- trol, cross-sectional, other design)	\boxtimes			9.1	there
3.2	Does the protocol specify whether the study is based on primary, secondary or combined data collection?	\boxtimes			9.2	onsthere
3.3	Does the protocol specify measures of occur- rence? (e.g., rate, risk, prevalence)	\square			997.1	
3.4	Does the protocol specify measure(s) of associa- tion? (e.g. risk, odds ratio, excess risk, rate ratio, hazard ra- tio, risk/rate difference, number needed to harm (NNH))			Ref		
3.5	Does the protocol describe the approach for the collection and reporting of adverse events/ad-verse reactions? (e.g. adverse events that will not be collected in case of primary data collection)		alla al		11	
Comn	nents:	Silo	,			-
	a ta	0/10				
			1		1	1
<u>Sec</u> t	ion 4: Source and study populations	Yes	No	N/A	Section Number	
4.1	Is the source population described?	\square			9.2.1	
4.2	Is the planned study population defined in terms of:					
	4.2.1 Study time period	\square			9.2.2	
	4.2.2 Age and sex	\square			9.2.3	
	4.2.3 Country of origin	\square			9.2	
	4.2.4 Disease/indication	\square			9.2.3	
	4.2.5 Duration of follow-up	\square			9.2.3	
4.3	Does the protocol define how the study popula- tion will be sampled from the source population? (e.g. event or inclusion/exclusion criteria)				9.2.4 and 9.2.5	
Comn	nents: Ø					
	<u>, v</u>					1

	anot				
Sec	tion 5: Exposure definition and measurement	Yes	No	N/A	Section Number
THIS HOCUL 5.1	Does the protocol describe how the study expo- sure is defined and measured? (e.g. operational de- tails for defining and categorising exposure, measurement of dose and duration of drug exposure)				9.3.1

<u>Sec</u>	ion 5: Exposure definition and measurement	Yes	No	N/A	Section Number	
5.2	Does the protocol address the validity of the ex- posure measurement? (e.g. precision, accuracy, use of validation sub-study)		\boxtimes			nsthereof.
5.3	Is exposure categorised according to time win- dows?	\boxtimes			9.3.1	ons
5.4	Is intensity of exposure addressed? (e.g. dose, duration)				orvan	
5.5	Is exposure categorised based on biological mechanism of action and taking into account the pharmacokinetics and pharmacodynamics of the drug?				SIONS	
5.6	Is (are) (an) appropriate comparator(s) identi- fied?	\square		\mathcal{L}	9.3.1	
Comn	nents:	×10	and			

	1	JICC.			
<u>Sec</u> t	ion 6: Outcome definition and measurement	Yes	No	N/A	Section Number
6.1	Does the protocol specify the primary and sec- ondary (if applicable) outcome(s) to be investi- gated?	\boxtimes			9.3.2
6.2	Does the protocol describe how the outcomes are defined and measured?	\boxtimes			9.3.2
6.3	Does the protocol address the validity of outcome measurement? (e.g. precision, accuracy, sensitivity, spec- ificity, positive predictive value, use of validation sub-study)	\boxtimes			9.3.2
6.4	Does the protocol describe specific outcomes rel- evant for Health Technology Assessment? (e.g. HRQoL, QALYS, DALYS, health care services utilisation, burden of disease or treatment, compliance, disease manage- ment)				

Comments:

0.0

	Sect	tion 7: Bias	Yes	No	N/A	Section Number
	<u>R</u> I	Does the protocol address ways to measure con- founding? (e.g. confounding by indication)	\boxtimes			9.9
This docu	7.2	Does the protocol address selection bias? (e.g. healthy user/adherer bias)	\boxtimes			9.9
4his	7.3	Does the protocol address information bias? (e.g. misclassification of exposure and outcomes, time-related bias)	\boxtimes			9.9

٦

Comments:

<u>Sec</u>	tion 8: Effect measure modification	<u>Yes</u>	<u>No</u>	<u>N/A</u>	<u>Section</u> <u>Number</u>
8.1	Does the protocol address effect modifiers? (e.g. collection of data on known effect modifiers, sub-group analyses, anticipated direction of effect)				9.3.3.2
Comr	nents:				orve
					ons
<u>Sec</u>	tion 9: Data sources	Yes	No	NŽA	Section Number
9.1	Does the protocol describe the data source(s) used in the study for the ascertainment of:		and st		
	9.1.1 Exposure? (e.g. pharmacy dispensing, general prac- tice prescribing, claims data, self-report, face-to-face in- terview)				9.3.1
	9.1.2 Outcomes? (e.g. clinical records, laboratory mark- ers or values, claims data, self-report, patient interview including scales and questionnaires, vital statistics)	\boxtimes			9.3.2
	9.1.3 Covariates and other characteristics?	\square			9.3.3
9.2	Does the protocol describe the information avail- able from the data source(s) on:				
	9.2.1 Exposure? (e.g. date of dispensing, drug quantity, dose, number of days of supply prescription, daily dosage, prescriber)				9.4
	9.2.2 Outcomes? (e.g. date of occurrence, multiple event, severity measures related to event)				9.4
	9.2.3 Covariates and other characteristics? (e.g. age, sex, clinical and drug use history, co-morbidity, co-medications, lifestyle)				9.4
9.3	Is a coding system described for:				
	9.3.1 Exposure? (e.g. WHO Drug Dictionary, Anatomical Therapeutic Chemical (ATC) Classification System)	\square			9.4
	9.3.2 Outcomes? (e.g. International Classification of Diseases (ICD), Medical Dictionary for Regulatory Activities (MedDRA))				9.4
C	9.3.3 Covariates and other characteristics?				9.4
9.4	Is a linkage method between data sources de- scribed? (e.g. based on a unique identifier or other)				9.4
Comr	nents:				

Section 10: Analysis plan	Yes	No	N/A	Section Number	
10.1 Are the statistical methods and the reason for their choice described?	\square			9.7	ns thereof.
10.2 Is study size and/or statistical precision esti- mated?				9.5	onstill
10.3 Are descriptive analyses included?	\boxtimes			9.7.1.1	
10.4 Are stratified analyses included?	\boxtimes			9.7.1.1.2	
10.5 Does the plan describe methods for analytic con- trol of confounding?				9.7.1.1.2	
10.6 Does the plan describe methods for analytic con- trol of outcome misclassification?			A Contraction	9.9	
10.7 Does the plan describe methods for handling missing data?	\square		\mathcal{L}	9.6.5	
10.8 Are relevant sensitivity analyses described?	\square	ŝ		9.9	
Comments:	tion				
	olico				
	<u> </u>				

Section 11: Data management and quality control	Yes	No	N/A	Section Number				
11.1 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)	\boxtimes			9.6				
11.2 Are methods of quality assurance described?	\boxtimes			9.8				
11.3 Is there a system in place for independent review of study results?	\boxtimes			10				
Comments:								
o ^r								

	- NC				
	Section 12: Limitations	Yes	No	N/A	Section Number
	12.1 Does the protocol discuss the impact on the study results of:				
	12.1.1 Selection bias?	\bowtie			9.9
	12.1.2 Information bias?	\boxtimes			9.9
AOCU!	12.1.3 Residual/unmeasured confounding? (e.g. anticipated direction and magnitude of such biases, vali- dation sub-study, use of validation and external data, analyti- cal methods).	\boxtimes			9.7.1.1.2
This docu	12.2 Does the protocol discuss study feasibility? (e.g. study size, anticipated exposure uptake, duration of fol- low-up in a cohort study, patient recruitment, precision of the estimates)	\boxtimes			9.5

1

Comments:

Section 13: Ethical/data protection issues	Yes	No	N/A	Section Number
13.1 Have requirements of Ethics Committee/ Institu- tional Review Board been described?	\square			5.5
13.2 Has any outcome of an ethical review procedure been addressed?		\boxtimes		5.5
13.3 Have data protection requirements been de- scribed?				510 ⁷⁷⁵ 10
Comments:			ette	
			[c, c]	
Section 14: Amendments and deviations	Yes	No	N/A	Section Number
14.1 Does the protocol include a section to document amendments and deviations?				5
Comments:	*			
Section 15: Plans for communication of study re- sults	Yes	No	N/A	Section Number
15.1 Are plans described for communicating study re- sults (e.g. to regulatory authorities)?	\square			12
15.2 Are plans described for disseminating study re- sults externally, including publication?				12
Comments:				
SUP				
Solution accounted for constraining study residuation Comments: Name of the main author of the protocol: Date: dd/Month/year Signature:				
Date: dd/Month/year				
Signature:				

APPENDIX 3. LIST OF DIAGNOSIS CODES FOR STUDY OUTCOMES

A recent study has validated the coding of hospital diagnosis for infection with high PPV in Denmark (Holland-Bill et al, 2014). The list of infection types included, and the ICD-10 codes used to identify them are detailed here:							
The list of infection types inc here:	cluded, and the ICD-10 co	odes used to identify them are detailed	onsthe				
Specific infection types	Broad infection types	Diagnostic codes according to the Danish version of the ICD-10					
Pneumonia	Respiratory tract infection	J139, J151, J152, J157, J159, J180, J481					
Other respiratory tract infection	Respiratory tract infection	J189, B599, J019, J039, J209, J320					
Intestinal infection	Intestinal infection	A047, A099, B962, K122, K350, K359, K570, J573, K610, K611, K612, K810, K811					
Cellulitis or erysipelas	Skin infection	N469, L030, L031, L038, L089					
Other skin infection	Skin infection	L021, L022, L029, H620					
Bladder infection	Urinary tract infection	N300, N309					
Kidney infection	Urinary tract infection	N109, N151					
Other urinary tract infection	Urinary tract infection	N390					
Endocarditis	Endocarditis	Y330					
Meningitis	Intracranial infection	B003					
Bacteremia	Bacteremia	A499, N499A					
Sepsis	Sepsis	A408, A409, A410, A412, A415, A418, A419, B377					
Osteomyelitis	Bone/joint infection	M860					
Septic arthritis	Bone/joint infection	M009					
Tuberculosis	Tuberculosis	A169, A180					
Aspergillosis	Aspergillosis	B440					
Other	Other	B370, B378, K122, H031, H702					

ICD-10=International Classification of Diseases, revision 10

Serious infections will be identified in all the contributing databases as any of the above codes (or equivalent mapped code/s) for infection associated with a hospital admission and/or resulting in mortality. This results in 3 possible outcomes that will be included for analyses in the main study

Serious infection diagnosis leading to hospital admission (primary outcome). This will be defined as the presence of 1 of the conditions above recorded as part of the diagnoses recorded in a hospital admission where hospital or claims data are available. Where linked hospital or claim records are not available (HSD [Italy] and IPCI [Netherlands]), the above diagnoses will be identified from primary care records, and free text reviewed for all such potential cases to identify those with evidence of a related hospital admission.

hisdocum

- In-hospital death with a diagnosis of infection during the same admission (secondary outcome). This will be defined as the presence of 1 of the conditions above recorded as part of the diagnoses recorded during a hospital admission that resulted in an in-hospital death. Where linked hospital or claim records are not available (HSD [Italy] and IPCI [Netherlands]), the outcome below (#3) will be used instead.
 Recorded diagnosis of any infection in either primary or secondary or secondary of followed by death in the subsection.
- The boundary of the second paper of the second 3. Recorded diagnosis of any infection in either primary or secondary care/hospital records, infection in any patient clinical data (primary or secondary care records or claims) followed

APPENDIX 4. VALIDATION PROCESS FOR STUDY OUTCOMES

Briations thereof. Validation studies will be conducted for the study outcome, ie, SI/s for all databases except CPRD (UK) and the nationwide linked Danish registers. The results from validation studies from Denmark have been reported previously (Holland-Bill et al, 2014).

As for CPRD (UK), a number of validation studies have been reported on different types of specific infections.

First author	Year of publication	Journal/Reference	Specific infection type validated
Aberra	2007	Clinical Gastroenterol and Hepatol 5: 1070-1075	Tuberculosis
De Wilde	2004	Health Statistics Quarterly 22: 21	Impetigo
De Wilde	2004	Health Statistics Quarterly 22: 21	Measles
De Wilde	2004	Health Statistics Quarterly 22: 21	Rubella
De Wilde	2004	Health Statistics Quarterly 22: 21	Scabies
De Wilde	2004	Health Statistics Quarterly 22,21	Urinary tract infection
De Wilde	2004	Health Statistics Quarterly 22: 21	Viral illness
Jick	2006	Arthritis and rheumatism 55(1): 19-26	Tuberculosis
Van Staa	1994	Pharmacoepidemiology and Drug Safety 3: 15-21	Urinary tract infection
Van Staa	1994	Pharmacoepidemiology and Drug Safety 3: 15-21	Respiratory infection

None of them have previously validated the diagnosis of infection or serious/hospital infection.

Serious infections are defined for the proposed studies as a combination of 1 or more infection codes with either evidence of a hospital admission or a related death.

- Hospital admissions will be identified using linked data in SIDIAP (Spain) (linked to loco-regional hospital admissions data in the so called Conjunto Mínimo de Datos [CMBD] database), CPRD (UK) (linked to English national hospital admissions data in the Hospital Episode Statistics [HES] Admitted Patient Care database), national health registers in Denmark, and claims in SNDS (France) and GePaRD (Germany), and therefore, do not need validation.
- Databases with no linkage to either hospital or claims data (HSD [Italy] and IPCI [Netherlands]) will review free text for all potential cases for comparative safety analysis (amongst eligible users of romosozumab or ALN in the study period) to identify related hospital admissions for the identification of potential cases. Medical charts, hospital This document letters and any other documents available will be reviewed by medical students and/or medical doctor.
 - Finally, death has either been previously validated or will be validated as part of the concomitant CV PASS.

Therefore, it is the diagnosis of infection/s that needs validation. Sample validation studies of 250 cases will be needed from all the contributing databases except nationwide linked Danish registries (Denmark) and CPRD (UK).

Variations thereof. For all others, validations in primary care databases (SIDIAP, HSD, and IPCI) will be based on free text review of the individual cases. Primary care charts and any related documents (eg, specialist letters, referrals) will be reviewed by clinically trained validators using prespecified algorithms.

As for validations in GePaRD (Germany) and SNDS (France), a combination of plausibility of diagnoses and case reviews will be used as recently described (Wentzell et al, 2018). This 2-step process consists of the following stages:

- 1. Plausibility" of diagnoses: Characterization of potential "case" patients (eg, regarding age, sex, risk factors, comorbidity), and assessment of related diagnostic procedures, treatment/s initiated, follow-up, and outcome/s (eg, duration of hospitalization, mortality).
- data w ation will e algorithm w and automation and automation and automation 2. External validation: the proposed (and refined as based on information from 1) case ascertainment algorithm/s are applied to external data where case review is possible (eg, from academic collaborating hospitals). Case verification will be based on information from the hospital records, and PPVs calculated for the algorithm used in GePaRD and SNDS

Confidential

Page 59 of 59